Here are four things to know:
1. The system is aimed to improve patients' postoperative primary total knee arthroplasty rehabilitation and reduce associated postacute care costs.
2. CyMedica President and CEO Rob Morocco said, "This clinical trial will allow us to accelerate what we believe is an essential shift in the care model for total knee post-surgical rehabilitation."
3. The device addresses the issues associated with patients' lack of quadriceps strength after knee surgery.
4. Patients often have to pay up to $4,200 to treat post-surgical muscle atrophy with rehabilitation and have a higher likelihood of readmissions.
More articles on devices:
Baxter highlights FLOSEAL hemostatic agent enhancements for spine, cardiac surgery: 5 highlights